Does Humana Cover Addyi (Flibanserin)? Coverage, Prior Auth, and Appeals Explained

What Is Addyi and Why Does Coverage Get Complicated?

Addyi (flibanserin 100 mg) is the only FDA-approved non-hormonal treatment for generalized acquired HSDD in premenopausal women. Coverage disputes arise because insurers frequently miscategorize it alongside hormonal or lifestyle drugs rather than recognizing it as a central nervous system serotonin 1A agonist / serotonin 2A antagonist approved for a defined psychiatric-sexual diagnosis.

Flibanserin was approved by the FDA on August 18, 2015, after two prior complete-response letters required additional safety data on alcohol interaction [1]. The approval carried a Risk Evaluation and Mitigation Strategy (REMS) program due to the hypotension and syncope risk with alcohol, which was later modified in 2019 [2]. That REMS history gives some insurers a reason to impose extra utilization management steps, including PA requirements and safety attestations.

The BEGONIA trial (N=1,378, published Journal of Sexual Medicine 2014) showed flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) versus placebo at 24 weeks, with a mean increase of approximately 0.5 additional SSEs per 28 days (P<0.001) [3]. A companion phase III trial, VIOLET (N=1,267), confirmed the SSE benefit and also showed improvement on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score [4]. These two trials formed the core of the NDA submission that led to approval.

Insurers want to see that diagnosis coding matches these trial populations precisely. Using the wrong ICD-10 code, for example, F52.9 (unspecified sexual dysfunction) instead of F52.0 (hypoactive sexual desire dysfunction), is one of the most common reasons Humana denies a PA at the first submission.

The FDA's prescribing information specifies that flibanserin is indicated for premenopausal women only [1]. Humana's PA criteria typically mirror that restriction. Postmenopausal patients or male patients will almost always receive a denial on clinical grounds, not just formulary grounds.

Humana Commercial Plans: Formulary Tier and Prior Authorization

On Humana commercial (employer-sponsored and individual ACA) plans, Addyi most often appears on Tier 3 or Tier 4, costing members $60 to $150 per 30-day fill depending on the specific plan design. A small number of Humana commercial plans exclude it entirely as a non-covered benefit.

To verify your specific plan, log in to the Humana member portal and run a drug search at humana.com/pharmacy. The formulary lookup tool shows tier placement, PA requirement, and quantity limits (typically 30 tablets per 30 days) in real time. Do not rely on a benefits summary document from open enrollment, Humana updates formularies on January 1 each year and may make mid-year changes for new drugs.

Standard PA criteria on Humana commercial plans for Addyi typically include:

1. Confirmed diagnosis of generalized acquired HSDD coded as F52.0.
2. Patient is premenopausal (documented in chart; some plans accept FSH level or clinical notation).
3. Distress criterion met, often documented by a validated tool such as the FSDS-R score of 11 or greater [5].
4. Absence of contraindicated medications (moderate or strong CYP2C19 inhibitors, strong CYP3A4 inhibitors, and alcohol-containing products).
5. Prescriber attestation that the patient has received alcohol risk counseling (a REMS requirement) [2].
6. For some plans: documentation that psychotherapy or sex therapy was offered or tried, though this is not universally required.

A PA approval from Humana commercial is typically valid for 12 months, after which reauthorization is needed. The prescribing clinician's office submits the PA via CoverMyMeds, Surescripts, or Humana's provider portal. Average first-pass approval rates for Addyi PA submissions nationally hover around 55 to 65 percent based on specialty pharmacy data, meaning roughly one in three patients needs a peer-to-peer review or appeal from the start.

Humana Medicare Advantage: Why Coverage Is Almost Always Denied

Medicare Advantage plans, including all Humana MA plans, must follow CMS coverage policy. CMS does not recognize Addyi as a covered Part D drug for most beneficiaries because Medicare Part D historically excludes drugs "used for cosmetic purposes or hair growth" and drugs "used to promote fertility, used for symptomatic relief of cough or colds, used to promote weight loss, or used for erectile dysfunction" under 42 CFR 423.120 [6].

HSDD is not erectile dysfunction and is not a weight-loss indication, but CMS has not issued a national coverage determination (NCD) or formal Part D exception policy specifically covering flibanserin. The result is that most Humana MA plans list Addyi as a non-covered drug outright [6].

Patients enrolled in Humana Medicare Advantage who are still premenopausal (for example, women under 55 on disability Medicare) can try a coverage exception request, but approval rates are low. The exception pathway requires the prescribing physician to submit a written statement that no other covered drug is adequate, along with clinical notes supporting the HSDD diagnosis [6]. CMS guidance on exceptions is available at cms.gov.

If the exception is denied, the next step is an independent review by MAXIMUS Federal Services, the contracted Medicare Part D Independent Review Entity. MAXIMUS reviews must be requested within 60 days of the coverage denial notice. MAXIMUS upheld about 23 percent of all Medicare Part D appeals in the most recent CMS annual report data, so odds are modest, though patients with well-documented clinical need do succeed [6].

Step Therapy: Does Humana Require It for Addyi?

Some Humana commercial plans impose a step therapy requirement before approving Addyi. This means the plan wants documentation that a patient tried and failed a prior treatment before flibanserin can be covered.

The complication: there is no FDA-approved drug for HSDD in premenopausal women other than flibanserin itself (and bremelanotide, sold as Vyleesi, approved June 2019 for a slightly different patient profile) [7]. Step therapy requiring failure of another approved drug therefore has no clinical basis for this indication, and 29 states plus the District of Columbia have passed step therapy override laws requiring plans to grant exceptions when no clinically appropriate alternative exists [8].

If Humana's PA denial letter cites step therapy and you are in a state with a step therapy override law, your physician can submit an override request citing that state statute. The American Urological Association and the International Society for Sexual Medicine both note in published position statements that there is no evidence base supporting a step-through requirement for HSDD given the absence of therapeutic alternatives [9].

Some plans accept documented participation in cognitive behavioral therapy (CBT) or sex therapy as the "prior step," which is clinically reasonable given that the FDA label recommends using flibanserin as part of a broader treatment plan [1]. If CBT has been tried, include session dates and the therapist's name in the PA packet.

How to Appeal a Humana Denial of Addyi

A denial is not a final answer. The appeal process for Humana commercial plans follows a defined timeline under ACA and ERISA rules.

Step 1: Internal appeal. Submit within 180 days of the denial notice for non-urgent requests (or 72 hours for urgent situations). Include a letter of medical necessity from the prescriber, the relevant clinical notes, any validated HSDD assessment scores (FSDS-R, FSFI domain scores), and published clinical guidelines. The BEGONIA trial data [3] and the VIOLET trial data [4] are appropriate supporting literature. Humana must respond within 60 days for non-urgent appeals.

Step 2: Peer-to-peer review. Request that the prescribing clinician speak directly with the Humana medical director handling the denial. Peer-to-peer reviews convert approximately 30 to 40 percent of initial denials to approvals nationally. Schedule this call within 10 business days of the denial.

Step 3: External independent review. If the internal appeal is denied, you have the right to request an external review through an independent review organization (IRO) certified in your state. For self-insured ERISA employer plans, the external reviewer is assigned by the U.S. Department of Labor. The IRO must respond within 45 days for standard requests, or 72 hours for expedited requests. IRO decisions are binding on Humana for fully insured plans.

For Medicare Advantage patients, the MAXIMUS appeal follows a parallel timeline: request reconsideration within 60 days, then ALJ hearing if the MAXIMUS value at issue exceeds $180 (it will for a monthly Addyi prescription), then Medicare Appeals Council, then federal district court [6].

Document every denial letter, every call, and every submission date. The date stamp matters for both state and federal appeal deadlines.

Manufacturer Savings Card and Cash-Pay Options

Sprout Pharmaceuticals (the Addyi manufacturer) offers a savings card program for commercially insured patients. As of 2025, eligible patients with commercial insurance may pay as little as $25 to $99 per month at participating pharmacies. The program is not valid for patients enrolled in Medicare, Medicaid, CHIP, TRICARE, or any other federal or state government health program [10].

To activate the savings card, the patient or prescriber downloads it from the official Addyi website or requests a card through the specialty pharmacy. Mark Health and Edgepark Pharmacy are common specialty distributors for Addyi due to the REMS requirements.

Cash-pay price at retail pharmacies runs approximately $800 to $900 per month for 30 tablets. GoodRx and similar discount programs do not consistently reduce this price significantly because flibanserin lacks a generic equivalent and is not widely stocked at standard retail pharmacies. Patients who are denied Humana coverage and do not qualify for the manufacturer savings card should ask the prescribing office about any available patient assistance programs directly through Sprout.

Documenting HSDD Correctly to Support a PA

Insurance approval starts with a well-constructed chart. Weak documentation is the single most correctable reason PA submissions fail.

The DSM-5 criteria for Female Sexual Interest/Arousal Disorder (FSIAD), which maps closely to ICD-10 F52.0 for coding purposes, require that at least three of six symptom criteria are present for a minimum of 6 months and cause clinically significant distress [11]. Humana's PA reviewers look for that 6-month duration explicitly.

Validated scoring tools that strengthen a PA packet include the Female Sexual Function Index (FSFI), where a total score below 26.55 indicates sexual dysfunction [12], and the Female Sexual Distress Scale-Revised (FSDS-R), where a score of 11 or above indicates clinically meaningful distress [5]. Including both scores with dates in the medical necessity letter gives the Humana reviewer objective data rather than narrative-only documentation.

Other chart elements that support approval: menstrual cycle history confirming premenopausal status, medication review confirming absence of CYP2C19 or CYP3A4 inhibitors, and a note documenting that the patient was counseled on the alcohol interaction risk as required under the REMS program [2].

What Prescribers Need to Know Before Submitting to Humana

Prescribers bear most of the practical burden in getting Addyi covered. A few procedural points reduce the chances of a first-pass denial.

Use diagnosis code F52.0 as the primary code on both the prescription and the PA form. Some EHR systems autofill F52.9 or F52.8; verify the code manually before submission. Attach the chart note that documents distress duration of at least 6 months, includes an FSFI or FSDS-R score, and confirms premenopausal status. Include the REMS counseling attestation language.

If your state has a step therapy override law, include a one-sentence statement in the PA letter: "No FDA-approved therapeutic alternative for generalized acquired HSDD in premenopausal women other than flibanserin (and bremelanotide for different patient profiles) exists; step therapy requirements are therefore clinically unsupported and subject to state override." Cite the applicable state statute by name.

Humana's fax-based PA line for pharmacy benefits is listed on the back of the member ID card and in the Humana provider portal. CoverMyMeds integration is available for most Humana commercial plans. Allow 3 to 5 business days for initial PA review; urgent PA requests for patients mid-cycle can be flagged as urgent but HSDD rarely qualifies as medically urgent under plan criteria.

Drug Interactions That Can Affect Both Safety and Coverage

Humana's PA criteria and the FDA label both flag specific drug interactions that may trigger denial or require clinical justification.

Fluconazole, a moderate CYP2C19 inhibitor, is contraindicated with flibanserin [1]. If a patient is on fluconazole chronically (for example, for recurrent vulvovaginal candidiasis), the PA reviewer will flag this. The prescriber should address the interaction plan in the PA letter, which may include timing separation or antifungal therapy substitution.

Strong CYP3A4 inhibitors including clarithromycin, itraconazole, ketoconazole, ritonavir, and nefazodone are also contraindicated [1]. A patient on HIV therapy with ritonavir will not be a candidate for flibanserin until an alternative antiretroviral regimen is considered. Documenting this clinical reasoning shows the reviewer that the prescriber has engaged with the safety profile thoughtfully.

Alcohol is the most clinically significant interaction. The REMS program requires patient counseling and attestation that alcohol will be avoided for at least 2 hours after taking flibanserin at bedtime [2]. A PA that omits the REMS attestation will be returned for completion, adding days to the approval timeline.

Bremelanotide (Vyleesi) as a Coverage Alternative

If Humana denies Addyi specifically, bremelanotide (Vyleesi, approved June 21, 2019) is a second FDA-approved option for HSDD in premenopausal women [7]. It works through a different mechanism (melanocortin receptor agonism) and is self-administered as a subcutaneous injection up to 45 minutes before anticipated sexual activity, not as a daily oral tablet.

Humana's formulary treatment of Vyleesi varies by plan, but in some cases plans that deny Addyi will cover Vyleesi, or vice versa. If a patient receives a final denial for Addyi after exhausting the appeal process, asking the prescriber to consider a Vyleesi PA submission is a reasonable next step rather than accepting no coverage at all.

The RECONNECT trials (two pooled phase III studies, total N=1,247) showed bremelanotide produced a statistically significant improvement in the FSDS-DAO desire domain score versus placebo (P<0.001) [7]. Including this trial in the clinical comparison when requesting a formulary exception or a step therapy override strengthens the argument that this drug class has strong evidentiary support.